← The library
Semax
research/region-specificCognition/MoodEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeCognition / Neuroprotection
MechanismNeuropeptide analog studied for cognitive effects
EffectsNeuropeptide analog studied for cognitive effects
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteIntranasal; SC community only
FrequencyIntranasal typically 2x daily (morning + early afternoon)
StartingNo formal titration ("beginning with lower ranges")
EscalationNone described
TargetIntranasal about 0.6-1.5 mg/day split morning + early afternoon. SC: "sub-milligram per administration".
CycleShort 10-14 days; extended 4-6 weeks; cycled 4-6 on / 2-4 off
Registered in Russia; human evidence is Russian clinical literature. Essentially no SC human data.
Batches on filenone
No tested batches on file.
Cautions & interactions
Regulatory status varies; avoid unsupervised use
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.